Elevation Pharmaceuticals has announced positive results from a Phase 2b study of EP-101 in patients with chronic obstructive pulmonary disease (COPD), a progressive disease comprising chronic bronchitis and emphysema.

The Phase 2b randomised, placebo-controlled, double-blind, four-period cross-over, incomplete block design, dose-ranging, Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN-1) study evaluated the pharmacokinetics, safety and efficacy of EP-101 in 140 patients with moderate to severe COPD.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

EP-101 is a proprietary inhalation solution formulation of glycopyrrolate, a long-acting muscarinic antagonist (LAMA), delivered by PARI Pharma’s investigational eFlow nebuliser device, which employs eFlow technology to enable efficient aerosolisation of medications through a vibrating and perforated membrane.

Following seven days of treatment with EP-101, COPD patients had a clinically meaningful and considerable improvement in lung function when compared to placebo treatment.

“COPD patients had a clinically meaningful and considerable improvement in lung function.”

Bill Gerhart, Elevation Pharmaceuticals president and CEO, said the positive results from the first multi-dose trial of EP-101 are encouraging and support the company’s mission to improve the standard of care for patients with severe COPD.

“Pulmonologists are enthusiastic about the potential availability of a nebulised, once-daily LAMA and patients love the significant improvement in convenience offered by our new handheld delivery device,” Gerhart added.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the study, all doses of EP-101 met the primary endpoint of superior efficacy versus placebo, as measured by improved lung function, a 24-hour trough forced expiratory volume in one second (FEV1).

Elevation Pharmaceuticals chief medical officer Ahmet Tutuncu said the positive data from the Phase 2b study support continued development of the EP-101/eFlow combination for COPD patients.

The company is planning to begin a second Phase 2b study in the fourth quarter of 2012, to select the optimal dose of EP-101 for study in the pivotal Phase 3 programme.